Published: September 14, 2010
Cure Duchenne Announces Latest Events in the 2011 Cure Duchenne Adventures Series
CORONA DEL MAR, Calif. - (BUSINESS WIRE) - CureDuchenne, an Orange County-based nonprofit dedicated to finding a
cure for Duchenne Muscular Dystrophy (DMD), today announced the 3rd
annual Climb to CureDuchenne: Pick Your Peak and inaugural Tour de
CureDuchenne as a part of their signature fundraising series,
CureDuchenne Adventures. CureDuchenne Adventures will continue to engage
thrill-seekers, adventurers, and ordinary people in activities ranging
from mountaineering to cycling and other extraordinary adventures, all
while raising life-saving funds and building awareness for DMD research.
Following the success of the 2009 Climb to Cure Duchenne and 2010 Climb
to Cure Duchenne: Pick Your Peak - where groups of outdoor enthusiasts,
philanthropists, families of boys with DMD, and DMD advocates climbed
many of the US's most well-known peaks, including Mt. Rainier, Mt.
Shasta, Mt. Baldy, and Manitou Incline to raise awareness and more than
$400,000 for DMD research - CureDuchenne is pleased to announce the 2011
Climb to CureDuchenne: Pick Your Peak. The 2011 climb is set to take
place in June.
CureDuchenne Adventures aims to engage adventurers of all ages, skill
levels and interests. As such, in addition to the 2011 climb, the
nonprofit is announcing the 2011 Tour to CureDuchenne. This national
event encourages bicyclists from around the country to organize friends
and family and embark on bike rides of varying intensity. The event, set
for September 2011 will kick off with team registration in October 2010.
"As parents of a child with DMD, we want to build upon the success of
CureDuchenne Adventures in order to engage our supporters in any way
possible," said Debra Miller, CureDuchenne co-founder. "Aimed at
showcasing ordinary people accomplishing extraordinary feats, we've
added these two events to our 2011 plan to take extreme activities to
new philanthropic heights."
Founded in 2003 by Miller and her husband Paul following the devastating
diagnosis of their son at age five, CureDuchenne is a nonprofit
organization that raises awareness and funds specifically aimed at
finding a cure for DMD. As the leading genetic killer of young boys,
this devastating disease affects more than 1 in 3,500 boys worldwide and
is the most common and lethal form of Muscular Dystrophy.
Boys with DMD are usually diagnosed by the age of five, in a wheelchair
by age 12, and may be completely paralyzed by their late teens.
Historically, most patients with DMD do not live to see adulthood.
Duchenne can occur in any family, from any race and from any background.
CureDuchenne is challenging Americans to dedicate their
adventure-seeking activities to saving lives by participating in a
CureDuchenne Adventure and raising funds for research projects happening
around the world. Focused on getting the science out of the lab and into
human trials, CureDuchenne Adventures directly funds some of the leading
research for DMD patients. For example, at the organization's 2011
Duchenne Muscular Dystrophy Summit taking place in January in Southern
California, the scientific advisory board will identify the most
promising leads. These projects, earmarked to receive CureDuchenne
Adventure funding, will be announced following the January 2011 summit.
For more information or to sign up for CureDuchenne Adventures updates,
please visit www.cureduchenne.org
or follow CureDuchenne Adventures on Twitter: @CDadventures.
About CureDuchenne
CureDuchenne is a nonprofit organization that raises awareness and funds
specifically aimed at taking on Duchenne Muscular Dystrophy (DMD). By
working closely with the world's leading DMD scientists CureDuchenne
works to determine the most viable research projects that will
accelerate the clinical trial process and bring potential life saving
drugs to help this generation of young boys living with the deadly
disease.

The Fearey Group
Camille Carette
(206) 343-1543
ccarette@feareygroup.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News